| Description |
1 online resource (xiv, 253 pages) : illustrations |
| Series |
Falk symposium ; 157 |
|
Falk symposium (Series) ; 157.
|
| Contents |
Metabolic and toxic hepatitis -- NASH: bench to bedside: lessons from animal models -- Alcohol-induced hepatitis: pathophysiology and treatment -- Drug-induced hepatitis -- Cholestatic hepatitis -- Liver disease in pregnancy: diagnosis and treatment -- Geoepidemiology of primary biliary cirrhosis -- Interface hepatitis in primary biliary cirrhosis: prognostic marker and therapeutic target -- Viral hepatitis (part 1) -- Pathobiology of hepatitis B virus infection -- Individualized treatment of hepatitis C -- Viral hepatitis (part 2) -- Future in the treatment of hepatitis C -- Treatment of interferon non-responder patients with chronic hepatitis C in Asia -- Autoimmune hepatitis -- Update on autoimmune hepatitis -- Overlap syndromes -- Laudatio on the occasion of Professor Gerok's 80th birthday -- Wolfgang Gerok state-of-the-art lecture: pathogenesis of hepatic encephalopathy -- Sequelae of chronic hepatitis (part 1) -- Presentation of the international Dame Sheila Sherlock award -- Award lecture: past, present and future hepatology -- Progression of chronic hepatitis: from inflammation to fibrosis -- Treatment of portal hypertension and variceal bleeding -- Management of ascites and spontaneous bacterial peritonitis -- Sequelae of chronic hepatitis (part 2) -- Advances in the pathogenesis and treatment of type 1 and type 2 hepatorenal syndrome -- Hepatopulmonary syndrome -- Hepatocellular carcinoma |
| Summary |
This book is the proceedings of Falk Symposium 157, entitled Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune, held in Freiburg, Germany, on 10--11 October 2006 (one of three symposia during the XIII Falk Liver Week 2006). It provides up-to-date information on new developments in the field of chronic hepatitis and its various entities. In recent decades we have learned how heterogeneous the clinical entity of chronic hepatitis has become. The liver, as the central organ of metabolism and detoxification, is more than ever a target of disease processes evolving from the spread of obesity in the western world. Apart from nonalcoholic steatohepatitis (NASH), alcoholic liver disease is still the most prevalent liver disease in the west. Alcohol-induced liver disease exhibits a broad clinical spectrum from alcoholic steatohepatitis to cirrhosis. Alcoholic hepatitis is a disease entity with a particular poor prognosis. Any liver disease of unknown cause is suspected as being drug-associated. Every new drug metabolized in the liver has the potential to damage the liver. Primary biliary cirrhosis has seen significant progress due to the identification of new risk factors based on new epidemiological studies. Interface hepatitis has become a prognostic marker as well as a therapeutic target. The treatment of autoimmune hepatitis has progressed significantly due to an individualized approach to immunosuppression |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Chronic active hepatitis -- Congresses
|
|
Hepatitis, Chronic
|
|
Chronic active hepatitis.
|
| Genre/Form |
Conference papers and proceedings.
|
|
Conference papers and proceedings.
|
|
Actes de congrès.
|
| Form |
Electronic book
|
| Author |
Diehl, Anna Mae, editor.
|
|
Manns, Marianne, editor.
|
|
Hayashi, N. (Nariyuki), editor.
|
|
Sauerbruch, Tilman, editor.
|
| ISBN |
9781402065231 |
|
140206523X |
|
